RPTIX
Price
$97.75
Change
-$0.02 (-0.02%)
Updated
Sep 18 closing price
Net Assets
20.82B
RYMGX
Price
$58.92
Change
+$0.01 (+0.02%)
Updated
Sep 18 closing price
Net Assets
26.4M
Interact to see
Advertisement

RPTIX vs RYMGX

RPTIX vs RYMGX Comparison Chart in %
View a ticker or compare two or three
VS
RPTIX vs. RYMGX commentary
Sep 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPTIX is a Hold and RYMGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 20.8B vs. RYMGX (26.4M). RPTIX pays higher dividends than RYMGX: RPTIX (0.11) vs RYMGX (0.00). RPTIX was incepted earlier than RYMGX: RPTIX (11 years) vs RYMGX (22 years). RYMGX (1.59) is less costly to investors than RPTIX (0.63). RYMGX is a more actively managed with annual turnover of: 1337.00 vs. RPTIX (31.50). RYMGX has a lower initial minimum investment than RPTIX: RYMGX (2500) vs RPTIX (500000). RYMGX annual gain was more profitable for investors over the last year : 12.66 vs. RPTIX (-5.48). RYMGX return over 5 years is better than : -12.03 vs. RPTIX (-23.75).
RPTIXRYMGXRPTIX / RYMGX
Total Expense Ratio0.631.5441%
Annual Report Gross Expense Ratio0.631.5940%
Fund Existence11 years22 years-
Gain YTD0.16411.2751%
Front LoadN/A5%-
Min. Initial Investment500000250020,000%
Min. Initial Investment IRAN/AN/A-
Net Assets20.8B26.4M78,788%
Annual Yield % from dividends0.110.00-
Returns for 1 year-5.4812.66-43%
Returns for 3 years0.2824.881%
Returns for 5 years-23.75-12.03197%
Returns for 10 years28.9623.76122%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITYRX74.290.53
+0.72%
Invesco Technology R
GGQPX21.700.02
+0.09%
Goldman Sachs Mid Cap Growth P
FGDHX43.410.04
+0.09%
Fidelity Advisor® Dividend Growth I
SEMCX30.46-0.14
-0.46%
SEI Mid-Cap F (SIMT)
BRSSX16.50-0.08
-0.48%
MFS Blended Research Small Cap Eq R2